MEXICO CITY, Oct. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ('Genomma' or 'the Company'), a leading Mexican over-the-counter pharmaceuticals and personal care products company announced that it has no additional information related to today's stock price movements and considers that the variation in the stock price was singularly due to normal fluctuations due to the market conditions of recent days.

Additionally, Genomma reaffirms its sound financial structure in order to face the current situation:

    -- Genomma Lab has a considerable net cash position to fuel future growth.
    -- Genomma Lab is not exposed to derivative instruments.
    -- Genomma Lab does not have foreign currency denominated liabilities.

Due to its business model, strong capitalization and high profitability, the Company relies on its solid market position to continue growing in the coming years.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico and has a growing international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has significantly grown its revenue and profitability through a combination of a successful new product development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol 'LAB'.

Web Site: www.genommalab.com

SOURCE Genomma Lab Internacional, S.A.B. de C.V.